<DOC>
	<DOCNO>NCT01845792</DOCNO>
	<brief_summary>Patients ask take place research study advance prostate cancer gotten bad treatment . If join study receive new combination drug use treat prostate cancer .</brief_summary>
	<brief_title>Study Abiraterone Acetate Prednisone Combination With Cabazitaxel Patients With Prostate Cancer</brief_title>
	<detailed_description>Abiraterone acetate cabazitaxel approve United States Food Drug Administration ( FDA ) treat prostate cancer spread part body lymph node bone . These drug approve individually use cancer become resistant treatment , include chemotherapy docetaxel . The combination two drug evaluate , research team study safety effectiveness combination .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Written inform consent obtain . Adults 18 year age . Histologically cytologically proven adenocarcinoma prostate . Stage IV disease evidence soft tissue , visceral and/or bony metastasis must Response Evaluation Criteria Solid Tumors ( RECIST ) evaluable CT scan and/or bone scan Progressive disease receive hormonal therapy surgical castration document least one following : 1 . Increase measurable disease per RECIST 1.1 , 2 . Appearance new lesion bone scan consistent progressive prostate cancer ( &gt; 2 new lesion bone scan measure PD ) , 3. rise PSA define 2 sequential increase previous low reference value . Each value must obtain least 1 week apart . PSA least 2 ng/mL Received prior docetaxel chemotherapy Received prior abiraterone acetate , within 3 month prior study drug dosing . Testosterone level &lt; 50 ng/mL . Patients receive Leutinizing Hormone Releasing Hormone ( LHRH ) agonists antagonist must continue maintain castrate level testosterone study . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Adequate hematologic function : 1. platelet &gt; 100 , 000/uL ; 2. neutrophil count &gt; 1500 cell/mm3 ; 3. hemoglobin &gt; 9.0 g/dL ) Adequate renal function ( Creatinine clearance &gt; 50 mL/min ) Adequate potassium level ( &gt; 3.5 mEq/dL ) Adequate hepatic function 1. bilirubin &lt; 1.5 X upper limit normal ( ULN ) , 2. alanine aminotransferase ( ALT ) &lt; 1.5 X ULN , 3. aspartate aminotransferase ( AST ) &lt; 1.5 X ULN . 4. serum albumin ≥ 3.0 g/dL . Controlled blood pressure , define blood pressure ≤ 140/90 average ( 3 separate reading take screen visit relax clinical environment average ) Must able take oral medication without crush , dissolve chew tablet Willing take abiraterone acetate empty stomach ; ( 1 ) food consume least two hour least one hour dose abiraterone acetate take . Patients must willing able adhere prohibition restriction specify protocol . Written authorization use release health research study information obtain . Patients partner childbearing potential must willing use method birth control adequate barrier protection study 1 week last dose abiraterone acetate . Surgery radiation therapy within 2 week , Cytotoxic anticancer therapy within 3 week , Noncytotoxic anticancer therapy within 2 week , 5 halflives ( whichever short ) Study Day 1 . Prior radiotherapy ≥ 40 % bone marrow . Prior treatment Radium 223 . Use investigational therapeutic agent within 30 day . Have history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study agent . Prior treatment cabazitaxel . Known chronic infection human immunodeficiency virus ( HIV ) . Known active , symptomatic , brain metastasis . Blood pressure &gt; 140/90 average ( 3 separate reading take screen visit relax clinical environment average ) . History autoimmune disorder require daily corticosteroid therapy great prednisone 10mg daily , equivalent . Baseline peripheral edema &gt; grade 3 . Preexisting diarrhea uncontrolled supportive care ; Prior hemorrhagic diarrhea due ulcerative colitis , inflammatory bowel disease cause ; Active , uncontrolled peptic ulcer disease even set protonpump inhibitor Histamine2blocker use . Preexisting peripheral neuropathy grade &gt; 2 . Documented hypersensitivity ( CTCAE grade &gt; 2 ) drug contain polysorbate 80 . Have know allergy hypersensitivity abiraterone acetate prednisone excipients . Contraindications steroid use . Need medication strongly induce inhibit cytochrome P450 3A4 ( CYP3A4 ) cytochrome P450 2D6 ( CYP2D6 ) activity . ( see section 7.2.3 detail ) Serious infection require parenteral antibiotic within 14 day enrollment . Poorly control diabetes ( Hgb A1C &gt; 9 ) . Active symptomatic viral hepatitis Chronic liver disease , include ChildPugh Class B C liver disease . History pituitary adrenal dysfunction . Clinically significant heart disease evidence : 1. myocardial infarction , 2. arterial thrombotic event past 6 month , 3. severe unstable angina , 4 . New York Heart Association Class IIIIV heart disease , 5. cardiac ejection fraction measurement &lt; 50 % baseline . Consumption food beverage contain grapefruit juice within 7 day study drug dose Use firstgeneration antiandrogen : 1. bicalutamide within 6 week study drug dosing , 2. flutamide within 4 week study dose . Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castrate Resistant Prostate Cancer</keyword>
</DOC>